Cagrilintide
Cagrilintide targets amylin-related pathways involved in fullness and food intake. Human research has measured weight reduction, with the potential application and tolerability depending on the treatment and population studied.
Cagrilintide + SemaglutideIllustrative presentation
INFORMATIONAL REFERENCE
Cagrilintide + Semaglutide
This combination brings together Cagrilintide, Semaglutide. Explore each component’s research focus below, followed by the evidence for the combination.
Research focus & potential applications
Semaglutide
Semaglutide acts on the GLP-1 pathway involved in appetite and glucose regulation. Large human trials of defined medicines have demonstrated weight reduction in specified populations; the study summaries explain the magnitude, duration and limitations.
What the research shows
Explore the selected studies, their findings and their limits.
Cagrilintide
Read the findings & sources
Human study discussedA 26-week phase II trial in adults with overweight or obesity without diabetes reported mean weight reductions from 6.0% to 10.8% across cagrilintide groups, versus 3.0% with placebo in its trial-product analysis. Gastrointestinal symptoms, including nausea, were frequent. This supports study of amylin signaling in weight regulation, while leaving long-term outcomes and formulation-specific safety as separate questions.
Semaglutide
Read the findings & sources
Human study discussedSTEP 1 randomized 1,961 adults with overweight or obesity without diabetes. At 68 weeks, mean body-weight reduction was 14.9% with the studied semaglutide treatment versus 2.4% with placebo, with lifestyle support in both groups. Nausea and diarrhea were common; gastrointestinal events led to more treatment discontinuations. These are trial averages for a defined medicine and population, not predicted results from an AUREVIX preparation.
Evidence for the combination
Read the findings & sources
Human study discussedREDEFINE 1 randomized 3,417 adults without diabetes. The studied cagrilintide–semaglutide coadministration produced an estimated mean weight reduction of 20.4% at 68 weeks, versus 3.0% with placebo in the treatment-policy analysis. Gastrointestinal adverse events occurred in 79.6% versus 39.9%. This is evidence for that trial's coadministration, not proof that a separately manufactured premixed blend has matching stability, exposure, efficacy or safety.
For more information, contact info@aurevixpeptides.com.
Editorial review: September 23, 2026